Is Heron Therapeuti Stock a Good Investment?
Heron Therapeuti Investment Advice | HRTX |
- Examine Heron Therapeuti's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Heron Therapeuti's leadership team and their track record. Good management can help Heron Therapeuti navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Heron Therapeuti's business and its evolving consumer preferences.
- Compare Heron Therapeuti's performance and market position to its competitors. Analyze how Heron Therapeuti is positioned in terms of product offerings, innovation, and market share.
- Check if Heron Therapeuti pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Heron Therapeuti's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Heron Therapeuti stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Heron Therapeuti is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Heron Therapeuti Stock
Researching Heron Therapeuti's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 82.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.16. Heron Therapeuti had not issued any dividends in recent years. The entity had 1:20 split on the 13th of January 2014.
To determine if Heron Therapeuti is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Heron Therapeuti's research are outlined below:
| Heron Therapeuti generated a negative expected return over the last 90 days | |
| Heron Therapeuti has high historical volatility and very poor performance | |
| Heron Therapeuti has some characteristics of a very speculative penny stock | |
| Heron Therapeuti has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 127.04 M. Net Loss for the year was (110.56 M) with loss before overhead, payroll, taxes, and interest of (50.51 M). | |
| Heron Therapeuti currently holds about 83.54 M in cash with (58.79 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81. | |
| Heron Therapeuti has a frail financial position based on the latest SEC disclosures | |
| Over 82.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Heron Therapeutics, Inc. Short Interest Down 6.0 percent in October |
Heron Therapeuti uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Heron Therapeuti. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Heron Therapeuti's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Heron Therapeuti's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Heron Therapeuti's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-06 | 2024-06-30 | -0.04 | -0.06 | -0.02 | 50 | ||
2022-08-09 | 2022-06-30 | -0.5 | -0.55 | -0.05 | 10 | ||
2024-05-07 | 2024-03-31 | -0.09 | -0.02 | 0.07 | 77 | ||
2023-05-11 | 2023-03-31 | -0.2 | -0.27 | -0.07 | 35 | ||
2021-08-09 | 2021-06-30 | -0.55 | -0.62 | -0.07 | 12 | ||
2014-05-08 | 2014-03-31 | -0.67 | -0.74 | -0.07 | 10 | ||
2020-05-06 | 2020-03-31 | -0.65 | -0.57 | 0.08 | 12 | ||
2015-03-13 | 2014-12-31 | -0.79 | -0.71 | 0.08 | 10 |
Know Heron Therapeuti's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Heron Therapeuti is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Heron Therapeuti backward and forwards among themselves. Heron Therapeuti's institutional investor refers to the entity that pools money to purchase Heron Therapeuti's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 3.1 M | Jw Asset Management, Llc | 2024-09-30 | 2.3 M | Orchard Capital Management, Llc | 2024-06-30 | 2.2 M | Renaissance Technologies Corp | 2024-09-30 | 2 M | Congress Park Capital Llc | 2024-09-30 | 2 M | Tang Capital Management Llc | 2024-06-30 | 1.9 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 1.8 M | Monaco Asset Management | 2024-09-30 | 1.7 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.5 M | Rubric Capital Management Lp | 2024-06-30 | 26.7 M | Vanguard Group Inc | 2024-09-30 | 8.7 M |
Heron Therapeuti's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 170.35 M.Market Cap |
|
Heron Therapeuti's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.52) | |
| Return On Capital Employed | (0.77) | (0.81) | |
| Return On Assets | (0.50) | (0.52) | |
| Return On Equity | 3.25 | 3.42 |
Determining Heron Therapeuti's profitability involves analyzing its financial statements and using various financial metrics to determine if Heron Therapeuti is a good buy. For example, gross profit margin measures Heron Therapeuti's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Heron Therapeuti's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Heron Therapeuti's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Heron Therapeuti. Check Heron Therapeuti's Beneish M Score to see the likelihood of Heron Therapeuti's management manipulating its earnings.
Evaluate Heron Therapeuti's management efficiency
Heron Therapeuti has return on total asset (ROA) of (0.0231) % which means that it has lost $0.0231 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (24.0888) %, meaning that it created substantial loss on money invested by shareholders. Heron Therapeuti's management efficiency ratios could be used to measure how well Heron Therapeuti manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 3.42 in 2024, whereas Return On Tangible Assets are likely to drop (0.52) in 2024. At this time, Heron Therapeuti's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 35.4 M in 2024, whereas Other Current Assets are likely to drop slightly above 5.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.25) | (0.23) | |
| Tangible Book Value Per Share | (0.25) | (0.23) | |
| Enterprise Value Over EBITDA | (3.72) | (3.90) | |
| Price Book Value Ratio | (6.91) | (6.57) | |
| Enterprise Value Multiple | (3.72) | (3.90) | |
| Price Fair Value | (6.91) | (6.57) | |
| Enterprise Value | 871.2 M | 914.8 M |
Understanding the operational decisions made by Heron Therapeuti management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 1.809 |
Basic technical analysis of Heron Stock
As of the 22nd of November, Heron Therapeuti retains the Risk Adjusted Performance of (0.09), market risk adjusted performance of (0.28), and Standard Deviation of 5.02. Heron Therapeuti technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Heron Therapeuti's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Heron Therapeuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on Heron Therapeuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Heron Therapeuti insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Heron Therapeuti's Outstanding Corporate Bonds
Heron Therapeuti issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Heron Therapeuti uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Heron bonds can be classified according to their maturity, which is the date when Heron Therapeuti has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Heron Therapeuti's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Heron Therapeuti's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.28) | |||
| Mean Deviation | 3.11 | |||
| Coefficient Of Variation | (775.19) | |||
| Standard Deviation | 5.02 | |||
| Variance | 25.18 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.85) | |||
| Total Risk Alpha | (1.23) | |||
| Treynor Ratio | (0.29) | |||
| Maximum Drawdown | 38.9 | |||
| Value At Risk | (7.33) | |||
| Potential Upside | 4.5 | |||
| Skewness | (3.32) | |||
| Kurtosis | 18.57 |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.28) | |||
| Mean Deviation | 3.11 | |||
| Coefficient Of Variation | (775.19) | |||
| Standard Deviation | 5.02 | |||
| Variance | 25.18 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.85) | |||
| Total Risk Alpha | (1.23) | |||
| Treynor Ratio | (0.29) | |||
| Maximum Drawdown | 38.9 | |||
| Value At Risk | (7.33) | |||
| Potential Upside | 4.5 | |||
| Skewness | (3.32) | |||
| Kurtosis | 18.57 |
Consider Heron Therapeuti's intraday indicators
Heron Therapeuti intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Heron Therapeuti stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 98256.44 | |||
| Daily Balance Of Power | (0.86) | |||
| Rate Of Daily Change | 0.95 | |||
| Day Median Price | 1.09 | |||
| Day Typical Price | 1.08 | |||
| Price Action Indicator | (0.06) | |||
| Period Momentum Indicator | (0.06) | |||
| Relative Strength Index | 29.13 |
Heron Stock media impact
Far too much social signal, news, headlines, and media speculation about Heron Therapeuti that are available to investors today. That information is available publicly through Heron media outlets and privately through word of mouth or via Heron internal channels. However, regardless of the origin, that massive amount of Heron data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Heron Therapeuti news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Heron Therapeuti relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Heron Therapeuti's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Heron Therapeuti alpha.
Heron Therapeuti Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Heron Therapeuti can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Heron Therapeuti Corporate Management
| PharmD D | Executive Officer | Profile | |
| Barry PharmD | Chairman CEO | Profile | |
| Lisa Peraza | VP Officer | Profile | |
| Chris Storgard | Chief Officer | Profile |
Additional Tools for Heron Stock Analysis
When running Heron Therapeuti's price analysis, check to measure Heron Therapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heron Therapeuti is operating at the current time. Most of Heron Therapeuti's value examination focuses on studying past and present price action to predict the probability of Heron Therapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heron Therapeuti's price. Additionally, you may evaluate how the addition of Heron Therapeuti to your portfolios can decrease your overall portfolio volatility.